Form 4: ClearPoint Neuro Director Lynnette Fallon Settles Restricted Stock Units

Director Lynnette C. Fallon settled restricted stock units for shares of ClearPoint Neuro common stock on May 16, 2025.

Summary

• On May 16, 2025, Lynnette C. Fallon, a director of ClearPoint Neuro, Inc. (CLPT), settled 21,093 restricted stock units (RSUs) for shares of common stock.
• The RSUs vested on the earlier of the first anniversary of the grant date (May 16, 2024) or the day immediately preceding the company's 2025 annual meeting of stockholders.
• Following the transaction, Fallon beneficially owns 51,101 shares of CLPT common stock.
• The transactions were reported on a Form 4 filed with the SEC.
• Fallon has a Power of Attorney authorizing certain individuals to act on her behalf for Section 16 reporting purposes.

Sentiment

Score: 5

Explanation: This is a neutral event. It's a standard disclosure of an insider transaction related to previously granted compensation.

Positives

• The settlement of RSUs indicates that Fallon has met the vesting requirements, which could be seen as a positive sign of her continued involvement with the company.

Industry Context

This is a routine disclosure related to insider transactions and is common for publicly traded companies. It provides transparency into the holdings and transactions of company insiders.

Comparison to Industry Standards

• Form 4 filings are standard practice for publicly traded companies and their insiders, ensuring transparency in stock transactions.
• The vesting and settlement of restricted stock units are common forms of executive compensation, aligning the interests of management with those of shareholders.

Stakeholder Impact

• The transaction has a minimal direct impact on stakeholders, as it is a routine settlement of previously granted compensation.

Key Dates

Keywords

ClearPoint Neuro, CLPT, Lynnette Fallon, Restricted Stock Units, RSU, Form 4, Beneficial Ownership, Director, SEC Filing, Power of Attorney